TY - JOUR
T1 - Evaluation of gynecologic cancer with MR imaging,18F-FDG PET/CT, and PET/MR imaging
AU - Lee, Susanna I.
AU - Catalano, Onofrio A.
AU - Dehdashti, Farrokh
N1 - Publisher Copyright:
COPYRIGHT © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - MR imaging and 18F-FDG PET/CT play central and complementary roles in the care of patients with gynecologic cancer. Because treatment often requires combinations of surgery, radiotherapy, and chemotherapy, imaging is central to triage and to determining prognosis. This article reviews the use of the 2 imaging modalities in the initial evaluation of 3 common cancers: uterine cervical, uterine endometrial, and epithelial ovarian. Imaging features that affect management are highlighted, as well as the relative strengths and weaknesses of the 2 modalities. Use of imaging after initial therapy to assess for recurrence and to plan salvage therapy is described. Newer functional and molecular techniques in MR imaging and PET are evaluated. Finally, we describe our initial experience with PET/MR imaging, an emerging technology that may prove to be a mainstay in personalized gynecologic cancer care.
AB - MR imaging and 18F-FDG PET/CT play central and complementary roles in the care of patients with gynecologic cancer. Because treatment often requires combinations of surgery, radiotherapy, and chemotherapy, imaging is central to triage and to determining prognosis. This article reviews the use of the 2 imaging modalities in the initial evaluation of 3 common cancers: uterine cervical, uterine endometrial, and epithelial ovarian. Imaging features that affect management are highlighted, as well as the relative strengths and weaknesses of the 2 modalities. Use of imaging after initial therapy to assess for recurrence and to plan salvage therapy is described. Newer functional and molecular techniques in MR imaging and PET are evaluated. Finally, we describe our initial experience with PET/MR imaging, an emerging technology that may prove to be a mainstay in personalized gynecologic cancer care.
KW - 6α-F-fluoro-17β-estradiol PET
KW - Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone) PET
KW - Diffusion weighted imaging
KW - Dynamic contrast enhanced MRI
KW - Perfusion MRI
UR - http://www.scopus.com/inward/record.url?scp=84928155284&partnerID=8YFLogxK
U2 - 10.2967/jnumed.114.145011
DO - 10.2967/jnumed.114.145011
M3 - Article
C2 - 25635136
AN - SCOPUS:84928155284
SN - 0161-5505
VL - 56
SP - 436
EP - 443
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 3
ER -